



Sequella, Inc.
9610 Medical Center Drive
Rockville, MD 20850
Tele: 301-762-7776
www.sequella.com

MEDIA ADVISORY

May 2, 2007

Sequella To Present To Investors During BIO International Convention and Business Forum

WHO: Alan Klein, Executive Vice President of Corporate Development

WHAT: Sequella to present to investors and business partners during the BIO Business Forum held during the BIO International Convention in Boston. Sequella is a clinical-stage biopharmaceutical company focused on commercializing improved treatment paradigms for diseases of epidemic potential. The company leverages its global influence, infectious disease expertise, and diverse product portfolio to proactively address emerging health threats with significant market opportunity. The company's lead drug candidate, SQ109, is a new orally active diamine antibiotic for the treatment of tuberculosis (TB) and other infectious diseases. SQ109 has completed Phase 1a clinical studies and has received the FDA Fast Track designation. The company's lead diagnostic product candidate, the TB Patch, is completing several international clinical trials in anticipation of worldwide product registration.

WHEN: May 9, 2007/ 10:00 am

WHERE: BIO 2007 Business Forum
Boston Convention and Exhibition Center
(415 Summer St.) Level 1, Room (B) Infectious Disease Presentations

DETAILS: About the BIO International Convention, May 6-9, 2007 (Boston, MA)

The BIO Convention is considered the global event for biotechnology. It will draw more than 20,000 industry attendees, as well as 300 public officials from more than 30 countries and will host more than 1,800 exhibiting companies for four days showcasing the biotechnology industry and its global impact. <http://www.bio2007.org/>

###

For More Information Contact: Alicia Moran, Brightline Media, 703-739-2424 x110